Compare Ally Financial Inc (ALLY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Summit Therapeutics Inc — how do they compare? Ally Financial Inc trades at $43.92 (market cap $13.37B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Ally Financial Inc and Summit Therapeutics Inc are close in size by market cap, and Ally Financial Inc pays a 2.73% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ALLY | SMMT | |
|---|---|---|
Market Cap | $13.37B | $12.06B |
Sector | Financials | Health |
52-Week High | $47.25 | $26.98 |
52-Week Low | $35.96 | $12.55 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $44.14, up 0.8% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed earnings, beating estimates in Q1 2026 but missing in Q2, while maintaining a P/E of 10.34 and P/B of 0.99, indicating potential undervaluation. Recent news includes insider sales and corporate recognitions, alongside a declared $0.30 dividend payable in August 2026.
The outlook for ALLY is cautiously optimistic, with a consensus price target of $54.40 offering ~23% upside, though risks from higher provisions and macroeconomic pressures persist. Investment appeal lies in its low valuation and dividend, but investors must weigh credit risks and interest rate sensitivity against growth in auto finance and digital banking strengths.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
